Discounted Cash Flow (DCF) Analysis Levered
NGM Biopharmaceuticals, Inc. (NGM)
$17.09
+0.09 (+0.53%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
Revenue | 77.14 | 108.66 | 103.54 | 87.37 | 93.35 | 99.74 | 106.56 | 113.85 | 121.64 | 129.97 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue (%) | ||||||||||
Operating Cash Flow | -17.41 | -7.60 | -41.17 | -83.50 | -38.48 | -41.12 | -43.93 | -46.94 | -50.15 | -53.58 |
Operating Cash Flow (%) | ||||||||||
Capital Expenditure | -6.42 | -5.84 | -3.49 | -1.88 | -1.68 | -4.19 | -4.48 | -4.79 | -5.12 | -5.47 |
Capital Expenditure (%) | ||||||||||
Free Cash Flow | -23.83 | -13.44 | -44.66 | -85.37 | -40.17 | -45.31 | -48.41 | -51.72 | -55.26 | -59.04 |
Weighted Average Cost Of Capital
Share price | $ 17.09 |
---|---|
Beta | 1.693 |
Diluted Shares Outstanding | 77.41 |
Cost of Debt | |
Tax Rate | 1.74 |
After-tax Cost of Debt | -% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 10.838 |
Total Debt | 15.54 |
Total Equity | 1,322.92 |
Total Capital | 1,338.46 |
Debt Weighting | 1.16 |
Equity Weighting | 98.84 |
Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
Revenue | 77.14 | 108.66 | 103.54 | 87.37 | 93.35 | 99.74 | 106.56 | 113.85 | 121.64 | 129.97 |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | -17.41 | -7.60 | -41.17 | -83.50 | -38.48 | -41.12 | -43.93 | -46.94 | -50.15 | -53.58 |
Capital Expenditure | -6.42 | -5.84 | -3.49 | -1.88 | -1.68 | -4.19 | -4.48 | -4.79 | -5.12 | -5.47 |
Free Cash Flow | -23.83 | -13.44 | -44.66 | -85.37 | -40.17 | -45.31 | -48.41 | -51.72 | -55.26 | -59.04 |
WACC | ||||||||||
PV LFCF | - | - | - | - | - | - | ||||
SUM PV LFCF | - |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | - |
Free cash flow (t + 1) | -60.23 |
Terminal Value | - |
Present Value of Terminal Value | - |
Intrinsic Value
Enterprise Value | - |
---|---|
Net Debt | -136.26 |
Equity Value | - |
Shares Outstanding | 77.41 |
Equity Value Per Share | - |